Published by Iain Gilbert on 18th July 2025
(Sharecast News) - Drugmaker GSK said on Friday that the US Food and Drug Administration's Oncologic Drugs Advisory Committee had voted against the overall benefit/risk profile of its relapsed/refractory multiple myeloma asset at the proposed dosage.
URL: http://www.digitallook.com/dl/news/story/35226338/...